Abcl stock forecast.
Nov 13, 2023 · High Growth Earnings: ABCL is forecast to remain unprofitable over the next 3 years. Revenue vs Market: ABCL's revenue (23.9% per year) is forecast to grow faster than the US market (8% per year). High Growth Revenue: ABCL's revenue (23.9% per year) is forecast to grow faster than 20% per year.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.According to 10 stock analysts, the average 12-month stock price forecast for NIO Inc. stock is $12.44, which predicts an increase of 73.99%. The lowest target is $8.00 and the highest is $18. On average, analysts rate NIO Inc. stock as a buy.Find the latest AbCellera Biologics Inc. ABCL analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating.Stock Price Forecast. According to 14 stock analysts, the average 12-month stock price forecast for Palantir stock is $13.25, which predicts a decrease of -34.63%. The lowest target is $5.00 and the highest is $25. On average, analysts rate …AbCellera Biologics Stock Forecast. Is AbCellera Biologics Stock Undervalued? The current AbCellera Biologics [ ABCL] share price is $4.47. The Score for ABCL is 41, which is 18% below its historic median score of 50, and infers higher risk than normal. ABCL is currently trading in the 40-50% percentile range relative to its historical Stock ...
For AMERISOURCEBERGEN CORP stock forecast for 2023, 2 predictions are offered for each month of 2023 with average AMERISOURCEBERGEN CORP stock forecast of $186.62, a high forecast of $187.17, and a low forecast of $186.07. The average AMERISOURCEBERGEN CORP stock forecast 2023 represents a -0.54% decrease …Total Valuation. ABCL has a market cap or net worth of $1.37 billion. The enterprise value is $630.32 million. Market Cap. 1.37B. Enterprise Value. 630.32M.
AbCellera Biologics Inc. reported earnings of -$ 0.10 per ABCL share on Nov 2, 2023. AbCellera Biologics Inc. fell short of analysts' expectations by -28.57%. Meanwhile, the company posted an EPS of -$ 0.12 last year, which is a -193.33% lower compared to the same period last year. Report Date. Nov 2, 2023.Total Valuation. ABCL has a market cap or net worth of $1.37 billion. The enterprise value is $630.32 million. Market Cap. 1.37B. Enterprise Value. 630.32M.
The AbCellera Biologics Inc ( ABCL) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $10.03, representing a …2,065.00 -2.10(-0.10%) AbCellera Biologics Inc. (ABCL) NasdaqGS - NasdaqGS Real Time Price. Currency in USD Follow 2W 10W 9M 4.7800 +0.0500 (+1.06%) At close: 04:00PM EST 4.7600 -0.02 (-0.42%)... Nov 30, 2023 · View AbCellera Biologics Inc ABCL investment & stock information. Get the latest AbCellera Biologics Inc ABCL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Nov 29, 2023 · Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -618.82% from its current level, while the stock would need to crash -111.42% from its current level to reach the projected low. ABCL News. 14 days ago - AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023 - Business Wire 27 days ago - AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 - Business Wire 4 weeks ago - AbCellera Reports Q3 2023 Business Results - Business Wire 4 …
Price Performance Review of ABCL. On Monday, AbCellera Biologics Inc [NASDAQ:ABCL] saw its stock fall -4.79% to $4.47. On the same session, the stock had its day’s lowest price of $4.44, but rose to a high of $4.78. Over the last five days, the stock has gained 10.77%. AbCellera Biologics Inc shares have fallen nearly -55.82% since the year ...
About the AbCellera Biologics Inc stock forecast. As of 2023 November 28, Tuesday current price of ABCL stock is 4.530$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. AbCellera Biologics stock price has been showing a declining tendency so we believe that similar …
Find the latest AbCellera (NASDAQ: ABCL) stock information.Key points: Despite only being released into the Australian market a few months ago, Mounjaro is in short supply. It has been approved by the TGA as a …Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Key points: Despite only being released into the Australian market a few months ago, Mounjaro is in short supply. It has been approved by the TGA as a …We use big data and artificial intelligence to forecast the stock price of AbCellera Biologics Inc Ordinary Shares - ABCL. Our stock price predictions cover a period of 3 months. We cover the US equity market.
People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being... ABCL : 4.18 (-5.00%) 1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy Motley Fool - Thu Apr 13, 4:50AM CDT.25 sept 2023 ... AbCellera Stock Analysis | Why ABCL Stock is Falling. Nanalyze•4.5K ... | AAPL Stock Analysis | Apple Stock Price Prediction. Parkev Tatevosian ...AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F). Inflation hits lowest level since 2021, Fed's preferred gauge shows. Find the latest AbCellera Biologics Inc. (ABCL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight ...
Find the latest Bionano Genomics, Inc. (BNGO) stock quote, history, news and other vital information to help you with your stock trading and investing.Price target. 20.75R USD +16.32 +368.40%. The 8 analysts offering 1 year price forecasts for AbCellera Biologics Inc. have a max estimate of 34.00 and a min estimate of 10.00.
Whether it is the stock market, housing market, or livestock market, when confidence leaves it can have a big impact on prices. Cattle Australia deputy chair Garry …AbCellera Biologics Inc. reported earnings of -$ 0.10 per ABCL share on Nov 2, 2023. AbCellera Biologics Inc. fell short of analysts' expectations by -28.57%. Meanwhile, the company posted an EPS of -$ 0.12 last year, which is a -193.33% lower compared to the same period last year. Report Date. Nov 2, 2023.We use big data and artificial intelligence to forecast the stock price of AbCellera Biologics Inc Ordinary Shares - ABCL. Our stock price predictions cover a period of 3 months. We cover the US equity market.Analyst Forecast. According to 7 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price forecast is $22.33, which is an …ABCL Stock Analysis: Impressive Performance and Optimistic Analyst Forecasts ABCL stock had an impressive performance on September 20, 2023, based on the information provided. The 7 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 28.00, with a high estimate of 34.00 and a low estimate of 12.00.AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager (TCE) platform in two poster presentations at the American Society for Cancer Research (AACR) Annual Meeting 2023, which is being... ABCL : 4.18 (-5.00%) 1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy Motley Fool - Thu Apr 13, 4:50AM CDT.AbCellera Biologics (ABCL) is a biotech company that discovers antibodies from natural immune responses. The company has a consensus rating of Buy and a forecasted upside of 461.1% from its current price of $4.04. See the latest news, analysis, earnings, and insider trading of ABCL stock on MarketBeat.
This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $20.00 ,the lowest forecast is $10.00. The average price target represents 238.60% Increase from the current price of $4.43.
Given its relevancies, ABCL stock gained 13% of equity value in the trailing year. Still, ABCL surprisingly ranks among the most undervalued biotech stocks to buy. Currently, the market prices ...
According to our research, ABCL stock is a bad long-term investment. ABCL share price has been in a bear cycle for the past year. AbCellera Biologics Inc. …ABCL Forecast 2023. Check the latest forecasts. Read charts, analyst ratings, dividend and earningsHeading out for an outdoor adventure? Whether you’re planning a picnic, a hiking trip, or a beach day, one essential tool you need in your arsenal is a detailed weather 10 day forecast.Find the latest Aurora Cannabis Inc. (ACB) stock quote, history, news and other vital information to help you with your stock trading and investing.ABCL Earnings Date and Information. AbCellera Biologics last issued its quarterly earnings data on November 2nd, 2023. The reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The business earned $6.60 million during the quarter, compared to the consensus estimate of $11.92 million.Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -660.63% from its current level, while the stock would need to crash -123.71% from its current level to reach the projected low.AbCellera Biologics (ABCL) is a biotech company that discovers antibodies from natural immune responses. The company has a consensus rating of Buy and a forecasted upside of 461.1% from its current price of $4.04. See the latest news, analysis, earnings, and insider trading of ABCL stock on MarketBeat.All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...Despite the fact that AbCellera Biologics Inc. (NASDAQ:ABCL) stock rose 20% last week, insiders who sold US$389m worth of stock in the previous 12 months are likely to be better off.Dec 24, 2020 · About the AbCellera Biologics Inc stock forecast. As of 2023 November 28, Tuesday current price of ABCL stock is 4.530$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).
Based on 1 Wall Street analysts offering 12 month price targets for Orasure Technologies in the last 3 months. The average price target is $6.00 with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 6.57% change from the last price of $5.63. Highest Price Target $6.00. Average Price Target $6.00.The 8 analysts offering 1 year price forecasts for ABCL have a max estimate of — and a min estimate of —. Analyst rating Based on 9 analysts giving stock ratings to ABCL in the past 3 months.Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...Instagram:https://instagram. trading station reviewtyler tech stocktesla boxabl homeshort term lease insurance AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.01. This compares to earnings of $0.19 per share a year ago. These ...As a result, it might be a surprise to see that the analysts have cut their price target 10% to US$30.00, which could suggest the forecast improvement in performance is not expected to last. best mobile stock trading apphydrogen fuel companies Symbol Lookup from Yahoo Finance. Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance. best real estate to invest in 2023 Based on short-term price targets offered by eight analysts, the average price target for AbCellera Biologics Inc. comes to $20.75. The forecasts range from a low of $10.00 to a high of $32.00.The U.S. National Weather Service (NWS) is a part of the National Oceanic and Atmospheric Administration (NOAA). Many people rely on the National Weather Service’s forecasts in order to better anticipate what the weather will be like so the...